SCHEMBL720006

SCHEMBL720006

CCc1oc2ccccc2c1C(Nc1ccc(C(=O)N(C)CCC(=O)OC(c2c(CC)oc3ccccc23)C2CCCCC2)cc1)C1CCCCC1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.34
CYP2C19 P33261 1/20 0.34
KMT2A Q03164 3/20 0.34
HSD17B10 Q99714 3/20 0.34
ALDH1A1 P00352 2/20 0.34
MAPT P10636 1/20 0.34
HPGD P15428 1/20 0.34
ALOX15 P16050 1/20 0.34
VKORC1 Q9BQB6 2/20 0.33
EYA3 Q99504 2/20 0.32
SLC22A12 Q96S37 1/20 0.32
MEN1 O00255 2/20 0.32
HTT P42858 1/20 0.32
MCHR1 Q99705 1/20 0.32
ABL1 P00519 1/20 0.32
RIN1 Q13671 1/20 0.32
CYP2C9 P11712 2/20 0.31
HDAC6 Q9UBN7 1/20 0.31
TSHR P16473 1/20 0.31
TEAD4 Q15561 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL720542 0.90 CYP2C19 (0.37) TP53CYP2C19KMT2AHSD17B10ALDH1A1
SCHEMBL720005 0.87 CYP2C19 (0.35) TP53CYP2C19KMT2AHSD17B10ALDH1A1
SCHEMBL720495 0.79 TEAD4 (0.34) KMT2AHSD17B10MAPTMEN1ABL1
SCHEMBL719968 0.79 NPC1 (0.38) TP53KMT2AHSD17B10ALDH1A1MAPT
SCHEMBL719479 0.77 GCG (0.46) KMT2AHSD17B10ALDH1A1MAPTHPGD
SCHEMBL716552 0.76 NPC1 (0.40) TP53CYP2C19KMT2AALDH1A1MAPT
SCHEMBL721467 0.74 SSTR4 (0.35) HSD17B10ALDH1A1HTTABL1RIN1
SCHEMBL3402542 0.73 CASP3 (0.37) KMT2AALDH1A1MAPTMEN1NPC1
SCHEMBL719271 0.73 OPRM1 (0.41) ABL1RIN1HDAC6SLC6A2OPRM1
SCHEMBL720995 0.73 TSHR (0.39) TP53KMT2AALDH1A1MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP TP53 293/4885CYP2C19 946/4885KMT2A 1298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.